Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sakar HealthcareNSE:SAKAR +4.74%60 Pretax Margin % is 25.40% as of Mar. 2026, which is 94% above its 10-year median of 13.09. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹540.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Sakar Healthcare ranks better than 72.22% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sakar Healthcare Pretax Margin % Related Terms
Sakar Healthcare Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAKAR vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sakar Healthcare (NSE:SAKAR) has a Pretax Margin % of 25.40% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sakar Healthcare and its competitors. This is 94% above median its historical median of 13.09. Over the past decade, Sakar Healthcare's Pretax Margin % has ranged from 10.37 to 15.79. According to the industry distribution chart, Sakar Healthcare ranks #267 out of 961 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Sakar Healthcare's Pretax Margin % too high?
Sakar Healthcare's current Pretax Margin % of 25.40% is 94% above median its 10-year median of 13.09. Over the past 10 years, this metric has ranged from a low of 10.37 to a high of 15.79. The Drug Manufacturers industry median Pretax Margin % is 7.28. Sakar Healthcare's value of 25.40% is 248.9% above this industry median. Based on the distribution chart, Sakar Healthcare ranks #267 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #267 out of 961 companies for Pretax Margin %. This puts Sakar Healthcare in the upper half of its industry. The industry median Pretax Margin % is 7.28. Sakar Healthcare's value of 25.40% is 248.9% above this benchmark. Historically, Sakar Healthcare's own Pretax Margin % has ranged from 10.37 to 15.79 over the past decade. While the company's 10-year median is 13.09 vs. the industry median of 7.28, Sakar Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakar Healthcare's current Pretax Margin % of 25.40% is 248.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current Pretax Margin % is 25.40%, which is 94% above median its own 10-year median of 13.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current Pretax Margin % is 25.40%, which is 94% above median its 10-year median of 13.09 and 248.9% above the Drug Manufacturers industry median of 7.28. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Pretax Margin % is 25.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
Pretax Margin %: 25.40% (94% above median its 10-year median of 13.09)
GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
Industry Position: 248.9% above the Drug Manufacturers median (#267 of 961)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
